Dalbavancin: new single-dose antibiotic for acute skin infections

Xydalba (dalbavancin) is the first antibiotic to provide a full course of iv therapy for acute bacterial skin and skin structure infections in a single dose.

Dalbavancin is available as a powder for concentrate to be made up into a solution for infusion providing 20mg per ml.

The recommended adult dose is a single iv infusion of 1.5g given over 30 minutes or a single infusion of 1g followed by a 500mg dose one week later. Dalbavancin is not recommended in children and adolescents under 18 years of age.

Dalbavancin is a bactericidal lipoglycopeptide which demonstrates in vitro activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus.

The most commonly reported adverse effects with dalbavancin in clinical trials were headache, nausea and diarrhoea.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...